tbuckley/cabot-search huggingface dataset:
Pain slowly surrenders its secrets as research seeks opiates, new class of analgesics
Authors: C. Fletcher
Journal: JAMA (1984)

Developing safer opiates and a new class of nonopioid, centrally acting analgesics is among the goals of some 2,000 investigators who gathered in Seattle recently for the Fourth World Congress of the International Association for the Study of Pain. The diverse group of neurophysiologists, anesthesiologists, oncologists, pharmacologists, psychiatrists, and others attending the conference bears testimony to a burgeoning interest in pain research—a field that has blossomed, in the last two decades, on the borders between traditional disciplines. The potential impact of pain research is vast. In the United States alone, about 90 million people suffer from chronic pain, including the pain of low back ailments, arthritis, headaches, and cancer. John J. Bonica, MD, Department of Anesthesiology and Multidisciplinary Pain Center, University of Washington School of Medicine, Seattle, and past president of the association, says that pain accounts for 750 million lost work days a year and costs Americans at least
QOL-36. USE OF CANNABINOIDS IN THE PEDIATRIC CENTRAL NERVOUS SYSTEM TUMOR POPULATION
Authors: Kathleen Dorris, Jessica Channell, Ashley Mettetal, Molly Hemenway, Natalie Briones, Alexander Tran, Andrea Griesinger, Andrew Donson, Rajeev Vibhakar, Adam Green, Anandani Nellan, Jean Mulcahy Levy, Daniel Ambruso, Nicholas Foreman
Journal: Neuro-Oncology (2020)

Abstract BACKGROUND Cannabinoids, including cannabidiol (CBD) and tetrahydrocannabinol (THC), are a class of compounds found in marijuana. Numerous studies in adults have examined cannabinoid use in management of cancer-related symptoms such as nausea, anorexia, and pain. Less is known about the use in the pediatric oncology population. METHODS A prospective observational study has been ongoing since 2016 at Children’s Hospital Colorado to evaluate cannabinoids’ impact using PedsQL™ modules on quality of life of pediatric patients with central nervous system (CNS) tumors who are 2–18 years old. Laboratory assessments of T-cell activity and pharmacokinetics of CBD, THC and associated metabolites are in process. Diaries with exploratory information on cannabinoid use patterns are being collected. RESULTS Thirty-three patients (14:19; male:female) have been enrolled with a median age of 6.4 years (range, 2.9–17.7 years). The most common tumor type in enrolled patients is embryonal tumors (13/33; 39%). Nine (27%) patients have low-grade glial/glioneuronal tumors, and eight (24%) had high-grade/diffuse midline gliomas. The remaining patients had ependymoma or craniopharyngioma. The median time on cannabinoids is 9 months. Most (n=20) patients have used oral products with CBD and THC. One patient continues on cannabinoid therapy in follow up. Preliminary immune function analyses identified impaired neutrophil superoxide anion production and chemotaxis in patients taking cannabinoids at early time points on therapy. CONCLUSIONS Families of children with various CNS tumors are pursuing cannabinoid therapy for both antitumor and supportive care purposes. Analysis of the impact of cannabinoids on patients’ quality of life is ongoing.
Abstract 2253: Rapid personalized selection of immune checkpoint blockage agent combinational treatment for an adenocarcinoma patient
Authors: Kang-Yun Lee, Chien-Chung Chen, Won-Ting Huang
Journal: Cancer Research (2019)

Abstract The combination of immune checkpoint blockage (ICB) agent and chemotherapy for cancer treatment is gaining lots of attention lately. However, there is no clear biomarker or index for such treatment, particularly after tumor gaining resistance to ICI. In this study, an improved hollow fiber assay (HFA) was utilized based upon a novel substrate of microtube array membrane (MTAM) to test the possible patient response towards the combined treatment of immunotherapy and chemotherapy. In this case study, biopsy of a stage 4 adenocarcinoma (cT2N3M1b) patient, with the disease progression after a durable response to prior pemetrexed and Nivolumab, was retrieved and treated with enzyme for a homogenous cell suspension. Pieces of MTAM preloaded with 106 of cancer cell along with patient’s peripheral blood mononuclear cell (PBMC) were implanted subcutaneously in bulb C mice. These mice were grouped and subjected to two different ICB combinational treatments (1) Nivolumab with Paclitaxel and (2) Nivolumab with Pemetrexed. 10 days later MTAMs were explanted and cancer cells were subject to MTT assay for their viability. The results of two treatments clearly demonstrated the better efficacy of Nivolumab and Paclitaxel towards this patient cancer cells. Clinically, CT images taken before and after a two-month treatment show positive response towards the combinational treatment of Nivolumab and Paclitaxel. This case study suggests a rapid clinical regiment prediction/selection of ICB combinational treatment is possible in two weeks using MTAM/HFA and provides reasonable evident for the corresponding treatment. Citation Format: Kang-Yun Lee, Chien-Chung Chen, Won-Ting Huang. Rapid personalized selection of immune checkpoint blockage agent combinational treatment for an adenocarcinoma patient [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2253.
“Ethics for a Categorical Institution” Conference
Journal: JNCI Journal of the National Cancer Institute (1983)

Journal Article “Ethics for a Categorical Institution” Conference Get access JNCI: Journal of the National Cancer Institute, Volume 71, Issue 6, December 1983, Page 1347, https://doi.org/10.1093/jnci/71.6.1347-e Published: 01 December 1983
Racial/Ethnic Trends in Fetal Mortality—United States, 1990-2000
Journal: JAMA (2004)

Fetal deaths at > or =20 weeks' gestation account for 49% of all deaths that occur between the 20th week of pregnancy and the first year of life. Although the risk for fetal death has declined substantially since the 1950s, disparities in the risk for fetal death by race/ethnicity exist. One of the national health objectives for 2010 is to reduce deaths among fetuses of > or =20 weeks' gestation to 4.1 deaths per 1,000 live births plus fetal deaths for all racial/ethnic populations (objective no. 16-1a). To assess progress toward meeting this objective, CDC analyzed 1990-2000 data from the National Vital Statistics System (NVSS). The findings indicate substantial reductions in fetal deaths, primarily because of reductions in late fetal deaths (> or =28 weeks' gestation) compared with early fetal deaths (20-27 weeks' gestation). Despite these reductions, racial/ethnic disparities in fetal deaths persist, particularly among non-Hispanic blacks. Prevention strategies should recognize fetal deaths as a public health problem, improve fetal death surveillance and reporting, target etiologic research, and educate practitioners in identifying women at risk.
Reply
Authors: Ben L. Da, Christopher Koh, Theo Heller
Journal: Hepatology (2019)

Supported by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health. Potential conflict of interest: Nothing to report. We appreciate the interest in our work and the commentary provided by Professor Kumar and colleagues. To clarify, we do believe that hepatic venous pressure gradient (HVPG) measurement is a viable clinical tool that can be used in addition to liver biopsy in distinguishing noncirrhotic portal hypertension (NCPH) versus cirrhosis. However, this is rarely necessary unless tissue sample obtained during the biopsy is insufficient. Performance of HVPG measurements, compared with percutaneous liver biopsy, subjects patients to prolonged procedure times and requires additional allocation of medical resources, all while resulting in smaller and narrower cores that make histologic interpretation less reliable.1 The latter is the most crucial liability, as the tissue itself is the gold standard in differentiating NCPH from cirrhosis. Our main conclusion from our cohort is that outside of the possible diagnostic benefits (as demonstrated by a lower HVPG measurement), there does not seem to be any correlation to meaningful clinical outcomes such as ascites, varices, or mortality. In cirrhotic disease, these are the primary therapeutic benefits that drive the decision to measure the HVPG. It is also important to note that the prognosis of NCPH is directly linked to etiology, and recent literature from the Western world has suggested a significantly worse prognosis than previously thought.2 Accordingly, it may not be crucial to differentiate between NCPH and cirrhosis in certain patient populations that commonly develop NCPH.3 Finally, although transient elastography (TE) can be used to differentiate NCPH from cirrhosis, Vuppalanchi et al. demonstrated that there was significant overlap in liver stiffness measurements (LSM) between the two diseases.4 Mean LSM values of their NCPH compared with a matched cohort with cirrhosis was 13.2 ± 11.5 versus 26.6 ± 18.4 kPa. Furthermore, LSM has not been shown to have any correlation to any meaningful clinical outcomes in NCPH. Consequently, TE is unreliable in differentiating NCPH from cirrhosis and cannot be clinically used in the management of NCPH. Thus, our opinion continues to be that HVPG measurement is a limited clinical tool (both diagnostic and therapeutic) in NCPH. TE perhaps has more of a role in diagnosis because of its noninvasive nature, but results need to be interpreted with caution.
P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs).
Authors: Namrata Nayar, Nicola Jane Lawrence, Martin R. Stockler, Andrew James Martin, Sonia Yip, Nicole Wong, Annie Yeung, Michael Friedlander, Danish Mazhar, Farzana Pashankar, David I. Quinn, Ray McDermott, Rick Walker, Mark Winstanley, Fritha J. Hanning, Andrew James Weickhardt, Amanda Gwendolyn Stevanovic, Ian D. Davis, Guy C. Toner, Peter S. Grimison
Journal: Journal of Clinical Oncology (2018)

TPS574 Background: Bleomycin, etoposide, cisplatin (BEP) given 3-weekly x 4 remains standard 1st line chemotherapy for metastatic GCTs. Acceleration of standard regimen with shorter cycle lengths has improved cure rates in other cancers. This is the first international randomised clinical trial for intermediate and poor-risk metastatic extracranial GCTs involving both adult and paediatric age group males and females. We aim to determine if accelerated BEP is superior to standard BEP. Methods: DESIGN: Open label, randomised, stratified multicentre, 2 stage, phase 3 trial. Primary endpoint for stage I (n = 150) is complete response rate (RR), and for entire trial (n = 500) is progression free survival (PFS). SAMPLE SIZE: 150 and 500 patients gives &gt; 80% power to detect a 20% improvement in RR and 7% absolute improvement in 2yr PFS, respectively. POPULATION: Males and females aged 11-45 years with intermediate or poor-risk metastatic GCTs of the testis, ovary, retroperitoneum or mediastinum for 1st line chemotherapy. TREATMENT: Randomisation 1:1 to 4 cycles of “standard BEP” or “accelerated BEP”: cisplatin 20mg/m 2 IV days (D) 1-5; etoposide 100mg/m 2 IV D1-5; bleomycin 30000 IU IV (D 1, 8, 15 or D 2, 9, 16 of a 21 day cycle; D 1, 8 or D 2, 9 of a 14 day cycle); and peg G-CSF or Filgrastim; given every 3 weeks or every 2 weeks respectively. Accelerated BEP arm receives 4 additional weekly doses of bleomycin. ASSESSMENTS: Response assessments at 30 day safety assessment, and 6 months from randomisation or after all post-chemotherapy intervention is completed. Regular follow-up up to 5 years, then annually. Archival tumour tissue and baseline blood collected for translational substudies. STATUS: 25 sites open in ANZ, 1/19 sites open in UK (led by Cambridge Clinical Trials Unit), 41 patients recruited by September 2017. International collaborations with USA (led by Children’s Oncology Group) and Ireland (led by Cancer Trials Ireland) confirmed with sites expected to open by late 2017 and more sites sought for stage 2. Clinical trial information: NCT02582697.
Prey
Authors: Gary Stein
Journal: JAMA (2010)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ROCKY MOUNTAIN MEDICAL ASSOCIATION.
Journal: JAMA (1884)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
New Year, 1973
Journal: JAMA (2013)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Health Bills Pending in Congress
Authors: Franz Goldmann
Journal: New England Journal of Medicine (1946)

THE fight over a national health program is on. An unprecedented number of bills for the improvement and extension of health services is pending in Congress. We may be confused by this flurry of legislative activity and may differ in our opinions about the merits of these bills. But we may be said to be at heart on the side of any program designed to adjust the health services to the rapid progress of medical science and the profound socioeconomic changes that have taken place since the nineteenth century.Naturally and inevitably, one question is immediately raised. Is there any . . .
Correction: Initiating Antiretroviral Therapy for HIV at a Patient's First Clinic Visit: The RapIT Randomized Controlled Trial
Authors: Sydney Rosen, Mhairi Maskew, Matthew P. Fox, Cynthia Nyoni, Constance Mongwenyana, Given Malete, Ian Sanne, Dorah Bokaba, Celeste Sauls, Julia Rohr, Lawrence Long
Journal: PLoS Medicine (2016)

[This corrects the article DOI: 10.1371/journal.pmed.1002015.].
The Cover
Authors: M. T. Southgate
Journal: JAMA (1996)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Clinical Atlas of Venereal and Skin Diseases, Including Diagnosis, Prognosis and Treatment
Journal: JAMA (1889)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
QL-02 * HOPE AND MOOD CHANGES THROUGHOUT THE PRIMARY BRAIN TUMOR ILLNESS TRAJECTORY
Authors: A. Acquaye, E. Vera-Bolanos, L. Lin, M. R. Gilbert, T. S. Armstrong
Journal: Neuro-Oncology (2014)

The ambiguity of defining hope impacts the level of readiness faced by healthcare professionals in treating patients with glioma, a disease with an unpredictable outcome. While the initial focus of care is on the physiological effects of the disease, a sense of hope has been demonstrated to positively impact coping during illness in other cancer patients. This study describes the report of hope and the relationship between hope and mood in adult brain tumor patients at various points in the illness trajectory. This was a cross-sectional study with data collection including the use of the Herth Hope Index (HHI) within 3 subscales (temporality, readiness, interconnectedness), the Profile of Mood States-Short Form (POMS-SF) and clinical information. Descriptive statistics were used to report sample characteristics. Spearman's rho compared POMS-SF and HHI scores. 82 patients participated in the study ranging in age from 22 to 78 years (mean 44.78). Patients were primarily male (57.3%), married (76.8%) and employed (51.2%). The majority of patients had a high grade glioma (77%), with nearly half having a recurrence and over 20% on active treatment at the time of this study. The overall HHI total score for the sample was 41.32(range 13-48). Patients with recurrence had a low HHI interconnectedness (median = 14.00) score and higher total mood disturbance (median = 14.00) compared with patients without recurrence (HHI median = 15.00, Mood median = .00, p < .05). All negative mood states on the POMS-SF were negatively correlated with HHI subscales. Overall, patients reporting more hope also reported less overall mood disturbance (tension, anger, fatigue, depression, confusion). Patients with tumor recurrence reported lower hope and higher mood disturbance then those who were newly diagnosed or without recurrence. Targeting interventions specifically tailored to individual needs in improvement of quality of life throughout the disease course may include measures to address hope to facilitate positive coping strategies.
Impact of the Sequential IPV/OPV Schedule on Vaccination Coverage Levels—United States, 1997Osteoporosis Among Estrogen-Deficient Women—United States, 1988-1994FDA Approval of a Fourth Acellular Pertussis Vaccine for Use Among Infants and Young ChildrenImpact of the Sequential IPV/OPV Schedule on Vaccination Coverage Levels—United States, 1997Osteoporosis Among Estrogen-Deficient Women—United States, 1988-1994FDA Approval of a Fourth Acellular Pertussis Vaccine for Use Among Infants and Young …
Journal: JAMA (1999)
Lymphocele. A complication of cancer chemotherapy
Authors: W. B. Jones
Journal: JAMA (1978)

AS A COMPLICATION of surgery, the retroperitoneal lymphocele is not an uncommon entity. The incidence following radical pelvic surgery for carcinoma of the cervix has varied between 16% and 49%.<sup>1</sup>This complication has also been found after renal transplantation, the incidence being between 2% and 15%.<sup>2,3</sup>We report a case of retroperitoneal lymphocele as a complication of cancer chemotherapy; to our knowledge, this is the first such report. <h3>Report of a Case</h3> A 73-year-old woman went to her physician with the chief symptom of malaise. She had generalized adenopathy. Biopsy of an axillary node showed lymphosarcoma, and the patient was referred to Vanderbilt University Medical Center in November 1973. After review of the slides, the diagnosis of follicular, center cell, clonal-type lymphoma (Lukes and Collins) was made. Complete evaluation showed the patient to have stage IV-B disease. The lymphangiogram (Fig 1) showed involvement of the inguinal, iliac, and